Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
When it comes to identifying target stocks for investment, compelling prospects may include companies that are undervalued and, simultaneously, expected to appreciate in the future.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Medical device specialist DexCom (DXCM -0.33%) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader m...
3 Reasons Growth Investors Will Love DexCom (DXCM)
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) ...
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
5 Best Stocks of the S&P 500 ETF in the Past Month
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establ...
2 Growth Stocks to Buy and Hold for a Decade
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock ...
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, In...
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) ...
Related Companies